Stock · ABT · Healthcare
United States · Large Cap · listed since 1978 · Revenue 12 mo. $48.2B
Price as of 11/06/2026
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide.
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices. The company was formerly known as Abbott Alkaloidal Company and changed its name to Abbott Laboratories in 1915. Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.
Original text from the data provider
Summary
50.0 of 100
Mean of the six area values. Each area value is the mean of the stock's ranks among the companies in its sector. 50 is the middle of the sector, not a share of companies beaten.
Analysis
What the price requires
If free cash flow stays at €6.6B (2025), it supports €73.7B. The remaining €91.9B of the market value assume it grows 11.3% a year for 10 years and not at all afterwards.
Required FCF growth per year
11.3%
no growth afterwards
Price to operating cash flow 19.3×, below its usual range.
Middle half of 19 quarters: 20.3× to 25.8×, median 23.0×.
Measures only against its own past, not against what the company is worth. Price as of 11/06/2026.
with respect to the priced-in expectation
with respect to the priced-in expectation
Since the last quarter
Q2 → Q3 2026
3 more unchanged: Revenue, 12 mo., Gross margin, Shares outstanding
Derivation
Each area value is the average of its metrics' ranks within the sector (0 to 100, 50 is the middle). For metrics where lower is better, the rank is mirrored. The overall value is the average of the area values.
Price as of 11/06/2026.
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Return on equity | 12.51% | 11.52% | Rank 56 |
| Return on capital (Greenblatt) | 35.86% | 32.55% | Rank 57 |
| EBIT margin | 18.16% | 18.31% | Rank 49 |
| FCF margin | 16.68% | 14.12% | Rank 59 |
| Gross margin | 55.51% | 60.99% | Rank 42 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Revenue growth, 1 year | 5.67% | 8.04% | Rank 37 |
| Earnings growth, 3 years per year | −1.69% | 5.44% | Rank 31 |
| Earnings growth, 5 years per year | 8.21% | 7.00% | Rank 53 |
| Sustainable growth (ROE × retained earnings) | 4.90% | 3.66% | Rank 61 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Earnings yield | 3.40% | 2.90% | Rank 57 |
| FCF yield | 4.01% | 3.63% | Rank 53 |
| EV/saleslower is better | 4.30 | 4.03 | Rank 47 |
| EV/EBITlower is better | 23.70 | 21.73 | Rank 44 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Share price, 1 year | −21.63% | 8.66% | Rank 16 |
| Share price, 6 months | 30.86% | 24.27% | Rank 66 |
| Share price, 3 months | 7.10% | 15.42% | Rank 31 |
| Distance from 52-week high | −15.82% | −7.35% | Rank 28 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Accruals (Sloan)lower is better | −0.74% | 0.30% | Rank 60 |
| Change in share countlower is better | −0.06% | 0.00% | Rank 51 |
| Dividend streak in years | 12 | 10 | Rank 65 |
| Price reaction to results, market-adjusted | −2.42% | 0.05% | Rank 23 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Equity ratio | 60.12% | 48.40% | Rank 67 |
| Net debt/EBITDAlower is better | 0.51 | 1.11 | Rank 62 |
| Debt to equitylower is better | 0.29 | 0.48 | Rank 64 |
| Volatility, 1 yearlower is better | 27.59% | 31.42% | Rank 75 |
Ten years in figures
| Year | Revenue, $B | EBIT margin | FCF, $B | Shares | Net debt, $B |
|---|---|---|---|---|---|
| 2016 | 20.9 | 15.6% | 2.1 | 1.48B | 3.4 |
| 2017 | 27.4 | 7.2% | 4.4 | 1.75B | 18.5 |
| 2018 | 30.6 | 12.6% | 4.9 | 1.77B | 15.7 |
| 2019 | 31.9 | 14.4% | 4.5 | 1.78B | 15.2 |
| 2020 | 34.6 | 15.3% | 5.7 | 1.79B | 13.1 |
| 2021 | 43.1 | 21.4% | 8.6 | 1.79B | 9.5 |
| 2022 | 43.7 | 19.2% | 7.8 | 1.76B | 8.1 |
| 2023 | 40.1 | 16.0% | 5.1 | 1.75B | 9.0 |
| 2024 | 42.0 | 16.3% | 6.4 | 1.75B | 7.7 |
| 2025 | 44.3 | 18.2% | 7.4 | 1.75B | 6.5 |
4 of 7 StockScorer Score rules met · How the score is built
Abbott Laboratories mainly meets criteria in the Profitability category. Result from 18 strategies checked.
Abbott Laboratories is rated here with the StockScorer Score strategy, the flagship rule set. It compares return and cash-flow metrics with the median of the company's own sector and checks growth and price trend.
4 of 7 rules met
7 of 11 points
Detail data
Excerpt from 18 strategies checked. The full evaluation is visible after a free sign-up.
With a free account, you can see the match across all strategies checked in one complete overview.
Selected fundamental metrics for Abbott Laboratories.
| Metric | Stock | Sector |
|---|---|---|
| P/E ratio | 29.4 | 30.0 |
| P/B ratio | 3.7 | 4.8 |
| Return on equity (ROE) | 12.5% | 11.5% |
| Equity ratio | 60.1% | 48.4% |
| Debt-to-equity (D/E) | 0.29 | 0.48 |
| Dividend yield | 2.3% | 1.3% |
How comparable stocks in the same sector score in the StockScorer model.
| Symbol | Company | Rating |
|---|---|---|
| ABT | Abbott Laboratoriesthis page | |
| SYK | Stryker Corporation | Low4.5 |
| BSX | Boston Scientific Corp | High9.1 |
| EW | Edwards Lifesciences Corp | Low1.8 |
| MDT | Medtronic PLC | locked |
| SHL.DE | Siemens Healthineers AG | locked |
Signed up in 30 seconds, free.
Learn more about the metrics in the metrics glossary or all rated stocks in the stock overview.
How StockScorer rates every stock is explained on the methodology page.